Medical/Pharmaceuticals

MGI Tech Announces Acquisition of STOmics and CycloneSEQ to Deliver Integrated Long-Read, Short-Read and Spatial Omics Solutions

SHENZHEN, China, March 4, 2026 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive innovation in the life sciences, today announced the acquisition of STOmics and CycloneSEQ. It marks a significant milestone in MGI's "SEQALL+GLI+Omi...

2026-03-04 11:58 1445

Gene Solutions Announces Strategic Entry into Türkiye with Robust Real-World Evidence at the 2nd International Hereditary Cancers Congress 2026

In Partnership with ATC Genomics, the Company Presented One of Asia's Largest Real-World Datasets (n=12,281) for AI-Powered Multi-Cancer Early Detection (MCED) and Showcased its Clinically Validated ctDNA-Powered Oncology Portfolio Across the Full Cancer Continuum for High-Risk and Hereditary Pop...

2026-03-04 10:00 2035

Advancing Influenza Vaccine Development: Sino Biological Launches Antigens for the 2026-2027 Northern Hemisphere Influenza Vaccine Strains

HOUSTON, March 3, 2026 /PRNewswire/ -- The World Health Organization (WHO) has announced its recommendations for the 2026–2027 Northern Hemisphere influenza vaccine composition, highlighting the continued spread of A(H3N2) subclade K and emerging B/Victoria lineage strains. In rapid response, Sin...

2026-03-04 09:53 2121

PROTECTHEALTH STRENGTHENS GOVERNANCE AND SERVICE CONTINUITY WITH ISO 22301 BCMS CERTIFICATION

CYBERJAYA, Malaysia, March 4, 2026 /PRNewswire/ -- ProtectHealth Corporation Sdn. Bhd. has reinforced its role as a key government agency and strategic purchaser of healthcare services with the successful attainment of the ISO 22301:2019/AMD1:2024 Business Continuity Management System (BCMS) Cert...

2026-03-04 08:44 1414

Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases

* Antengene grants UCB worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, targeting B cell-related autoimmune diseases. * Antengene will receive USD 80 million of upfront and near-term milestone payments, and is e...

2026-03-04 06:00 1616

iClever Joins Forces with Renowned Audiologist Kellsie Busho to Champion Children's Hearing Health on World Hearing Day 2026

NEWARK, N.J., March 3, 2026 /PRNewswire/ -- As digital learning and personal audio devices become central to childhood, experts warn of rising risks of preventable hearing damage. Marking World Hearing Day, iClever, the No.1 selling kids' headphone brand in the U.S. online market, today announced...

2026-03-04 00:08 2998

HiRO Leads Cross‑Border Dialogue at JPM, Offering Insights for Biotechs Seeking Asian Investment

SOMERSET, N.J., March 3, 2026 /PRNewswire/ -- Harvest Integrated Research Organization (HiRO), a global contract research organization specializing in strategic planning for clinical development and cross‑border clinical trial solutions and services, concluded a successful presence at the 44th An...

2026-03-03 22:30 2115

Insilico Medicine and Liquid AI Announce Strategic Partnership Delivering Lightweight Scientific Foundation Models for Drug Discovery

Single 2.6B-parameter model achieves state-of-the-art performance across drug discovery benchmarks while running entirely on private pharmaceutical infrastructure CAMBRIDGE, Mass., March 3, 2026 /PRNewswire/ -- Insilico Medicine and Liquid AI today announced a partnership that creates lightweigh...

2026-03-03 22:25 2909

REPROCELL Launches GMP Master Cell Bank Manufacturing for Clinical iPSCs

Integrated Workflow Including Clinical Seed Production and StemEdit Gene Editing Services BELTSVILLE, Md., March 3, 2026 /PRNewswire/ -- REPROCELL (TYO: 4978) today announced the launch of its US FDA compliant Good Manufacturing Practice (GMP) Master Cell Bank (MCB) manufacturing service for hum...

2026-03-03 22:00 1446

Senhwa Biosciences Signs Major Strategic MOU with Y Combinator-Backed AI Biotech Company CellType to Accelerate the Evolution of CX-4945 into Version 2.0 and Reshape the Global Immunotherapy Landscape

TAIPEI and SAN DIEGO, March 3, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage company focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced the signing of a major strategic Memorandum of Understa...

2026-03-03 15:51 2423

Rosti Asia 2025 Review & 2026 Outlook: Building on Shared Success

SINGAPORE, March 3, 2026 /PRNewswire/ -- A report from Ringiertrade. Pat Williams, Senior Vice President of Rosti Asia, writes how Rosti Asia has performed strongly across its markets in 2025 despite challenges, as it looks forward to new opportunities in 2026. 2025 was a year of resilience, col...

2026-03-03 15:12 2028

Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China

* First glucokinase-activator (GKA) approval outside mainland China * Approval supports a differentiated approach to Type 2 diabetes (T2D) management * Hong Kong will serve as Hua Medicine's launchpad for international market expansion SHANGHAI and HONG KONG, March 3, 2026 /PRNewswire/ -- Hu...

2026-03-03 13:58 2314

/C O R R E C T I O N -- CooperVision, Inc./

In the news release, CooperVision Expands MyDay® MiSight® 1 day Myopia Control Soft Contact Lenses Into Asia Pacific Region, issued 02-Mar-2026 by CooperVision, Inc. over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with addition...

2026-03-03 10:27 3845

Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform

NEW YORK, March 3, 2026 /PRNewswire/ -- Royalty Pharma plc (Nasdaq: RPRX) announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company's royalty business in Asia. Ken joins Royalty Pharma from Morgan St...

2026-03-03 10:15 2662

The largest pharma show in Asia makes its return to Shanghai this June 2026

SHANGHAI, March 2, 2026 /PRNewswire/ -- CPHI & PMEC China 2026 is set to take place from 16 to18 June 2026 at the Shanghai New International Expo Centre (SNIEC), building on its extremely successful run over the last few years. As the world's premier destination for pharmaceutical ingredients and...

2026-03-03 10:15 2152

Bright Eye Clinic Achieves Government Accreditation Amid Korea's Medical Tourism Growth

SEOUL, South Korea, March 3, 2026 /PRNewswire/ -- Bright Eye Clinic announced its official accreditation under theKorean Accreditation Program for Hospitals Serving Foreign Patients (KAHF), administered by the Korea Health Industry Development Institute (KHIDI) ...

2026-03-03 10:00 2113

AsiaMedic Delivers Improved FY2025 Performance as Core Imaging Business Strengthens

* Financial performance strengthened alongside business expansion as newly added capacity are ramped up during the year * Profit attributable to owners of the Company doubled to S$2.0 million in FY2025 * Disposal of 60% interest in aesthetic business sharpens focus on core healthcare operat...

2026-03-03 09:40 2621

Efor strengthens its presence in Asia with the acquisition of No deviation

LYON, France, March 3, 2026 /PRNewswire/ -- Efor, a global leader specializing in quality and compliance for the Life Sciences industry, announces the acquisition of Singapore-based No deviation, a company recognized for its expertise in Commissioning, Qualification & Validation (CQV), Computer S...

2026-03-03 09:00 1928

US BioTek Laboratories Completes Merger With NutriPATH Pathology

SEATTLE and MELBOURNE, Australia, March 3, 2026 /PRNewswire/ -- US BioTek Laboratories, a leading functional laboratory specializing in advanced immunological and integrative diagnostics, today announced the completion of its merger with NutriPATH Pathology, a respected functional pathology labo...

2026-03-03 02:15 2192

Skyhawk Announces Australia's Therapeutic Goods Administration Has Determined SKY-0515 for Huntington's Disease Meets Eligibility Criteria for Registration via the Provisional Approval Pathway

Australia's Therapeutic Goods Administration (TGA), responsible for approval of the safety, quality, and efficacy of therapeutic goods, has determined that Skyhawk's SKY-0515 orally-administered small molecule therapy for the treatment of Huntington's disease meets TGA eligibility criteria for re...

2026-03-03 01:20 2798
12345 ... 645